These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20166790)

  • 21. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children.
    Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
    Mol Biol Rep; 2014 Jan; 41(1):331-6. PubMed ID: 24213830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
    Michelini G; Lenartowicz A; Vera JD; Bilder RM; McGough JJ; McCracken JT; Loo SK
    J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):415-426. PubMed ID: 35963559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Connor DF; Rubin J
    Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia.
    Jamroziak K; Balcerczak E; Smolewski P; Robey RW; Cebula B; Panczyk M; Kowalczyk M; Szmigielska-Kapłon A; Mirowski M; Bates SE; Robak T
    Pharmacol Rep; 2006; 58(5):720-8. PubMed ID: 17085864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.
    Taylor FB; Russo J
    J Clin Psychopharmacol; 2001 Apr; 21(2):223-8. PubMed ID: 11270920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study.
    Halperin JM; Newcorn JH; McKay KE; Siever LJ; Sharma V
    J Child Adolesc Psychopharmacol; 2003; 13(3):283-94. PubMed ID: 14642016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population.
    Issac MS; El-Nahid MS; Wissa MY
    Mol Diagn Ther; 2014 Feb; 18(1):73-83. PubMed ID: 24092646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; McBurnett K; White C; Youcha S
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.
    Connor DF; Grasso DJ; Slivinsky MD; Pearson GS; Banga A
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):244-51. PubMed ID: 23683139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
    Salatino-Oliveira A; Genro JP; Zeni C; Polanczyk GV; Chazan R; Guimarães AP; Callegari-Jacques SM; Rohde LA; Hutz MH
    Biol Psychiatry; 2011 Aug; 70(3):216-21. PubMed ID: 21550019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.
    Biederman J; Melmed RD; Patel A; McBurnett K; Donahue J; Lyne A
    CNS Spectr; 2008 Dec; 13(12):1047-55. PubMed ID: 19179940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
    Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
    Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the C3435T polymorphism of the multidrug resistance 1 gene on the severity of inflammatory bowel disease in Iranian Azeri Turks.
    Bonyadi MJ; Gerami SM; Somi MH; Khoshbaten M
    Saudi J Gastroenterol; 2013; 19(4):172-6. PubMed ID: 23828747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.